BI 1569912: Clinical Trials

5 trials of BI 1569912, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Terminated 1
Phase 21Completed 1

Follow BI 1569912: new trials by email Literature Review of BI 1569912 trials Research Report on BI 1569912

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
BI 1569912, Repaglinide, Midazolam - Healthy
Phase 1CompletedBoehringer Ingelheim182024-05-152026-05-22
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
BI 1569912, Placebo - Depressive Disorder, Major
Phase 2CompletedBoehringer Ingelheim2432024-03-272026-03-27
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
BI 1569912, Placebo - Healthy
Phase 1CompletedBoehringer Ingelheim832021-09-032026-06-26
A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
BI 1569912, Placebo - Healthy
Phase 1CompletedBoehringer Ingelheim562021-08-052026-05-22
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood
BI 1569912, Placebo - Healthy
Phase 1TerminatedBoehringer Ingelheim682020-07-212026-05-22

Conditions studied

Depressive Disorder, Major (1)

Sponsors

Boehringer Ingelheim (5)

Countries

Germany (3)  ·  Belgium (2)  ·  Japan (2)  ·  Bulgaria (1)  ·  China (1)  ·  Czechia (1)  ·  United States (1)

Results publications

PMID 42684025

NIH funding

2023 (2), 2019 (1)